Overview of immunotherapy in Alzheimer's disease (AD) and mechanisms of IVIG neuroprotection in preclinical models of AD.
about
Optimizing early Go/No Go decisions in CNS drug developmentProbabilistic Cost-Effectiveness Analysis of Vaccination for Mild or Moderate Alzheimer's DiseaseThe emerging role of bexarotene in the treatment of Alzheimer's disease: current evidence.Toxic species in amyloid disorders: Oligomers or mature fibrils.Induced dural lymphangiogenesis facilities soluble amyloid-beta clearance from brain in a transgenic mouse model of Alzheimer's disease.
P2860
Overview of immunotherapy in Alzheimer's disease (AD) and mechanisms of IVIG neuroprotection in preclinical models of AD.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Overview of immunotherapy in A ...... n in preclinical models of AD.
@en
Overview of immunotherapy in Alzheimer's disease
@nl
type
label
Overview of immunotherapy in A ...... n in preclinical models of AD.
@en
Overview of immunotherapy in Alzheimer's disease
@nl
prefLabel
Overview of immunotherapy in A ...... n in preclinical models of AD.
@en
Overview of immunotherapy in Alzheimer's disease
@nl
P2860
P1476
Overview of immunotherapy in A ...... n in preclinical models of AD.
@en
P2093
Debomoy K Lahiri
Scott E Counts
P2860
P304
P356
10.2174/156720501107140815102453
P577
2014-01-01T00:00:00Z